Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 78% Improvement Relative Risk Ventilation 94% Hospitalization 98% c19ivm.org Cadegiani et al. Ivermectin for COVID-19 EARLY Is early treatment with ivermectin+combined treatments beneficial for COVID-19? Prospective study of 247 patients in Brazil Lower ventilation (p=0.005) and hospitalization (p<0.0001) Cadegiani et al., New Microbes and New Infections, doi:10.1016/j.nmni.2021.100915 Favors ivermectin Favors control
Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient Settings Significantly Improved COVID-19 outcomes compared to Known outcomes in untreated patients
Cadegiani et al., New Microbes and New Infections, doi:10.1016/j.nmni.2021.100915 (date from earlier preprint)
Cadegiani et al., Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient.., New Microbes and New Infections, doi:10.1016/j.nmni.2021.100915 (date from earlier preprint)
Nov 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Comparison of HCQ, nitazoxanide, and ivermectin showing similar effectiveness for overall clinical outcomes in COVID-19 when used before seven days of symptoms, and overwhelmingly superior compared to the untreated COVID-19 population, even for those outcomes not influenced by placebo effect, at least when combined with azithromycin, and vitamin C, D and zinc in the majority of the cases. 585 patients with mean treatment delay 2.9 days. There was no hospitalization, mechanical ventilation, or mortality with treatment. Control group 1 was a retrospectively obtained group of untreated patients of the same population. This study is excluded in the after exclusion results of meta analysis: control group retrospectively obtained from untreated patients in the same population.
risk of death, 78.3% lower, RR 0.22, p = 0.50, treatment 0 of 110 (0.0%), control 2 of 137 (1.5%), NNT 68, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), control group 1.
risk of mechanical ventilation, 94.2% lower, RR 0.06, p = 0.005, treatment 0 of 110 (0.0%), control 9 of 137 (6.6%), NNT 15, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), control group 1.
risk of hospitalization, 98.0% lower, RR 0.02, p < 0.001, treatment 0 of 110 (0.0%), control 27 of 137 (19.7%), NNT 5.1, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), control group 1.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cadegiani et al., 4 Nov 2020, prospective, Brazil, peer-reviewed, 4 authors, average treatment delay 2.9 days, dosage 200μg/kg days 1-3, this trial uses multiple treatments in the treatment arm (combined with AZ, nitazoxanide (82), HCQ (22), spironolactone (66), dutasteride (4)) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: ORIGINAL ARTICLE Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients F. A. Cadegiani1,2, A. Goren2, C. G. Wambier3 and J. McCoy2 1) Corpometria Institute, Brasília, DF, Brazil, 2) Applied Biology, Inc., Irvine, CA and 3) Department of Dermatology, The Alpert Medical School of Brown University, RI, USA Abstract In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvements in COVID-19 outcomes when compared to untreated patients. The apparent yet likely positive results raised ethical concerns on the employment of further full placebo controlled studies in early-stage COVID-19. The present analysis aimed to elucidate, through a comparative analysis with two control groups, whether full placebo-control randomized clinical trials (RCTs) on early-stage COVID-19 are still ethically acceptable. The Active group (AG) consisted of patients enrolled in the Pre-AndroCoV-Trial (n = 585). Control Group 1 (CG1) consisted of a retrospectively obtained group of untreated patients of the same population (n = 137), and Control Group 2 (CG2) resulted from a precise prediction of clinical outcomes based on a thorough and structured review of indexed articles and official statements. Patients were matched for sex, age, comorbidities and disease severity at baseline. Compared to CG1 and CG2, AG showed reduction of 31.5–36.5% in viral shedding (p < 0.0001), 70–85% in disease duration (p < 0.0001), and 100% in respiratory complications, hospitalization, mechanical ventilation, deaths and post-COVID manifestations (p < 0.0001 for all). For every 1000 confirmed cases for COVID-19, at least 70 hospitalizations, 50 mechanical ventilations and five deaths were prevented. Benefits from the combination of early COVID-19 detection and early pharmacological approaches were consistent and overwhelming when compared to untreated groups, which, together with the well-established safety profile of the drug combinations tested in the PreAndroCoV Trial, precluded our study from continuing employing full placebo in early COVID-19. © 2021 The Author(s). Published by Elsevier Ltd. Keywords: Antiandrogen, clinical equipoise, COVID-19, dutasteride, hydroxychloroquine, ivermectin, nitazoxanide, proxalutamide, SARSCoV-2, spironolactone Article published online: 7 July 2021 Corresponding author: F.A. Cadegiani, Corpometria Institute, SGAS 915 Sala 260/262/264, Brasilia, DF, 70-390150, Brazil E-mails: flavio.cadegiani@unifesp.br, f.cadegiani@gmail.com Background Coronavirus Disease 2019 (COVID-19) is a highly heterogeneous and multi-systemic infection caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) [1] that is particularly harmful to those aged above 60 y/o, with uncontrolled diabetes, hypertension, obesity, androgenetic alopecia (AGA), abuse of anabolic steroids in males and hyperandrogenism in females [2–7]. Effective treatments to improve COVID-19 clinical outcomes, mortality and to prevent post-COVID manifestations are highly desired, while definitive solutions such as effective and safe vaccines are not universally available. Pharmacological interventions during the viral replication stage are likely the best timing to antagonize SARS-CoV-2 infectivity and prevent complications [1,3]. Hydroxychloroquine..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit